

Ref: STEX/OUTCOME/2024-25

Date: 11.02.2025

BSE Limited 25th Floor Phiroze Jeejebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
---	---

Sub. : Outcome of Board Meeting

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2024, were approved by the Board of Directors of the Company at its meeting held today at 2:00 P.M. and concluded at 03.30 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- The Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024; as **(Annexure- A)**
- Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter as **(Annexure-B)**
- Appointment of Mr. Chandan Kumar as Chief Financial Officer & Key Managerial Personnel of the Company. **(Annexure-C)**

We request you to take the same on record.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2024, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 31st December'2024

PART I

		Standalone						Consolidated					
		Three Month period Ended			Nine Months Ended		Year Ended	Three Month period Ended			Nine Months Ended		Year Ended
Particulars		31.12.2024 Unaudited	30.09.2024 Unaudited	31.12.2023 Unaudited	31.12.2024 Unaudited	31.12.2023 Unaudited	31.03.2024 Audited	31.12.2024 Unaudited	30.09.2024 Unaudited	31.12.2023 Unaudited	31.12.2024 Unaudited	31.12.2023 Unaudited	31.03.2024 Audited
1	Income from operations												
	(a) Net Sales / Income from operations	4,114.23	4,284.39	4,420.45	12,546.79	12,737.89	17,238.62	4,514.22	4,474.34	4,650.22	13,293.42	13,198.67	17,930.62
	(b) Other Income	14.08	28.96	83.05	100.56	175.95	230.26	14.07	28.96	83.05	101.66	175.95	232.57
	(c) Total Revenue	4,128.30	4,313.35	4,503.50	12,647.34	12,913.84	17,468.88	4,528.29	4,503.30	4,733.27	13,395.08	13,374.62	18,163.19
2	Expenses												
	a) Cost of Material Consumed	2,787.80	2,862.12	2,872.48	7,792.29	8,205.28	10,469.80	2,852.24	2,894.44	2,909.75	7,913.25	8,287.47	10,469.80
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(608.98)	(450.35)	(411.49)	(821.62)	(1,387.32)	(1,331.70)	(620.17)	(450.34)	(411.49)	(827.90)	(1,387.32)	(1,210.03)
	d) Employees Benefits Expenses	544.07	512.80	576.51	1,604.74	1,623.82	2,211.84	800.49	763.43	801.14	2,347.47	2,167.37	3,006.58
	e) Finance Cost	73.25	101.17	64.66	242.27	251.03	437.71	75.95	104.10	64.66	250.62	251.03	439.72
	f) Depreciation and Amortisation Expenses	217.26	257.22	175.94	648.69	523.53	700.84	220.97	260.73	180.49	658.73	531.88	709.32
	g) Other expenses	767.14	704.96	824.49	2,206.27	2,381.22	3,291.60	811.12	735.30	861.50	2,313.95	2,482.19	3,440.24
	Total Expenses	3,780.53	3,987.93	4,102.59	11,672.63	11,597.56	15,780.09	4,140.59	4,307.66	4,406.05	12,656.11	12,332.62	16,855.63
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	347.77	325.42	400.91	974.71	1,316.28	1,688.79	387.70	195.64	327.22	738.97	1,042.00	1,307.56
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	347.77	325.42	400.91	974.71	1,316.28	1,688.79	387.70	195.64	327.22	738.97	1,042.00	1,307.56
6	Tax Expenses												
	Current Year	102.57	105.25	98.61	291.38	342.57	421.69	102.57	105.25	98.61	291.38	342.57	421.69
	MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax Liability	(7.07)	(6.74)	25.67	(21.61)	(45.78)	(62.70)	(7.07)	(6.74)	25.62	(21.61)	(45.93)	(63.53)
	Total Tax Expense	95.50	98.52	124.28	269.77	296.79	358.99	95.50	98.51	124.23	269.77	296.64	358.16
7	Net Profit /Loss for the period from Continuing operation (5-6)	252.27	226.90	276.63	704.94	1,019.49	1,329.80	292.20	97.13	202.99	469.20	745.36	949.40

R. B. Bhatnagar



Particulars	Standalone						Consolidated					
	Three Month period Ended			Nine Months Ended		Year Ended	Three Month period Ended			Nine Months Ended		Year Ended
	31.12.2024 Unaudited	30.09.2024 Unaudited	31.12.2023 Unaudited	31.12.2024 Unaudited	31.12.2023 Unaudited	31.03.2024 Audited	31.12.2024 Unaudited	30.09.2024 Unaudited	31.12.2023 Unaudited	31.12.2024 Unaudited	31.12.2023 Unaudited	31.03.2024 Audited
8 Other Comprehensive Income												
Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	252.27	226.90	276.63	704.94	1,019.49	1,329.80	292.20	97.13	202.99	469.20	745.36	949.40
10 Net Profit /Loss attributable to												
a) Controlling Interest							347.45	152.38		524.45	880.32	1,093.10
b) Non-controlling Interest							(55.25)	(55.25)		(55.25)	(134.96)	(143.70)
10 Paid up equity share capital (Rs. 10/- per share)	1,271.46	1,271.46	1,265.11	1,271.46	1,265.11	1,271.46	1,271.46	1,271.46	1,265.11	1,271.46	1,265.11	1,271.46
11 Earning Per Share (Rs.)												
Basic	1.98	1.78	2.19	5.54	8.06	10.50	2.30	0.76	1.60	3.69	5.89	7.50
Diluted	1.98	1.78	2.19	5.54	8.06	10.50	2.30	0.76	1.60	3.69	5.89	7.50

NOTES :

- The Un-audited financial results for the quarter and nine months ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11th February, 2025
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- Limited Review has been carried out by the Statutory Auditors for the above period.
- The other expenses include the marketing expenses of Domestic market for both oncology & CVD which are yet to achieve break-even.
- Consolidated results of the company includes the results of its Associate i.e., Medicamen Life Sciences Pvt. Ltd., and Opal Pharmaceuticals Pty Ltd.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 11.02.2025

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi
(Rahul Bishnoi)
Chairman

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

**The Board of Directors,
Medicamen Biotech Ltd.**
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and nine months ended on December 31, 2024 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rai Qimat & Associates
Chartered Accountants**



**(Membership Number: 013152C)
UDIN: 25080857BMLCOG5836**

**Place: Gurugram
Date: 11.02.2025**

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its subsidiaries for the quarter and nine months ended on December 31, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited (the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and

other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statements includes the Group's share of net profit/(loss) after tax of Rs. 39.93 Lakhs and Rs. 235.74 Lakhs for the quarter and nine months ended on December 31, 2024 respectively, as considered in the consolidated unaudited financial results, in respect of its subsidiaries, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

**For Rai Qimat & Associates
Chartered Accountants**



**Rai Qimat Rai Garg
Partner
(Membership Number: 013152C)
UDIN: 25080857BMLCOH6217**

**Place: Gurugram
Date: 11.02.2025**

Annexure-C

Details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Particulars	Details
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment
Date of appointment / reappointment / cessation (as applicable) & term of appointment / reappointment;	February 11, 2025.
Brief profile (in case of appointment)	<p>Chandan Kumar is a CA (Inter) from ICAI, New Delhi & LLB from BRABU, Muzaffarpur. He has over 15 Years' experience in the areas of Accounting, Taxation & Auditing.</p> <p>Before joining MBL, he was associated with Brawn Laboratories Limited Delhi NCR (Pharmaceutical Company) for over 3.5 years as a HOD of Accounts & Audit Department. He has also worked with CLC Industries Limited, New Delhi over 4 Years as a Manager – Accounts Department, worked with Fena Private Limited over 4 Years as an Assistant Manager – Accounts & Audit Department & started his carrier as a Senior Account Executive from Arun Singh & Co. (CA Firm) with 4 Years.</p>
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable